Trubion Pharmaceuticals

Next-generation protein therapeutics for autoimmune and hematologic diseases

Trubion focused on creating protein therapeutics for autoimmune and hematologic oncology diseases. The company's products were based on several novel technology platforms to enhance or extend antibody-based therapeutics. Trubion completed its IPO on NASDAQ in 2006 and was acquired by Emergent BioSolutions in 2010.

Status

Acquired by Emergent BioSolutions in 2010

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Seattle, Washington

Frazier Team